P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of $^{11}$C-metoclopramide across the blood-brain barrier: a PET study on non-human primates

International audience; Rationale: PET imaging using radiolabeled high-affinity substrates of P-glycoprotein (ABCB1) has convincingly revealed the role of this major efflux transporter in limiting the influx of its substrates from blood into the brain across the blood-brain barrier (BBB). Many drugs, such as metoclopramide, are weak ABCB1 substrates and distribute into the brain even when ABCB1 is fully functional. In this study, we used kinetic modeling and validated simplified methods to highlight and quantify the impact of ABCB1 on the BBB influx and efflux of $^{11}$C-metoclopramide, as a model weak ABCB1 substrate, in non-human primates. Methods: The regional brain kinetics of a tracer dose of $^{11}$C-metoclopramide (298 ± 44 MBq) were assessed in baboons using PET without (n = 4) or with intravenous co-infusion of the ABCB1 inhibitor tariquidar (4 mg/kg/h, n = 4). Metabolite-corrected arterial input functions were generated to estimate the regional volume of distribution (V$_T$) as well as the influx (K$_1$) and efflux (k$_2$) rate constants, using a one-tissue compartment model. Modeling outcome parameters were correlated with image-derived parameters, i.e. area under the curve AUC$_{0-30}$$_{min}$ and AUC$_{30-60min}$ (SUV.min) as well as the elimination slope (k$_E$; min$^{-1}$) from 30 to 60 min of the regional time-activity curves. Results: Tariquidar significantly increased the brain distribution of $^{11}$C-metoclopramide (V$_T$ = 4.3 ± 0.5 mL/cm$^3$ and 8.7 ± 0.5 mL/cm$^3$ for baseline and ABCB1 inhibition conditions, respectively, P